Latest Regulatory News

Range International Limited reported a significantly reduced half-year loss alongside a 63% revenue increase, driven by strong pallet sales and resolution of Indonesian tax disputes. The company is now positioning for growth with factory relocations and new market entries.

TerraCom Limited reported a statutory loss of A$33.7 million for FY2025 amid lower coal sales and prices, while progressing its Moorlands Thermal Coal Project in partnership with Wintime Energy Group.

RLF AgTech Ltd has reported a remarkable financial turnaround in FY25, with revenues more than doubling and losses narrowing significantly, setting the stage for expansion in FY26.

Astron Limited has finalized its move from Hong Kong to Australia, issuing new securities on a two-for-one basis and preparing for ASX trading starting September 1, 2025.

Decidr AI Industries Ltd has reported a dramatic turnaround with a $71.1 million profit for FY2025, driven by its strategic acquisition of Decidr.ai Pty Ltd. The company is now moving to acquire full ownership of Decidr.ai, signaling a bold push into AI software.

Delorean Corporation reported a strategic shift in FY25, transitioning from third-party bioenergy construction to owning and operating renewable gas infrastructure, resulting in a $4.1 million loss but positioning the company for future multi-revenue growth.

Perpetual Resources has launched a prospectus to enable trading of new options issued alongside a recent $1.6 million placement, aiming to unlock liquidity while outlining key risks for investors.

Argent BioPharma reported a net loss of A$17.84 million for FY2025, reflecting a strategic pivot towards core drug development and clinical advancement. The company secured key EU approvals and raised significant capital to support its neuro-immune modulatory pipeline.

Singular Health Group reported a $6.38 million loss for FY2025 while securing a pivotal $1.3 million commercial agreement with US-based Provider Network Solutions to deploy its 3DICOM software. The company also completed a major cloud migration of its platform, positioning itself for growth in the US healthcare market.

Osteopore Limited reported a 6% increase in revenue to $1.56 million for the half-year ended June 2025, alongside a slight rise in net loss driven by expanded product development and compliance costs. The company secured key regulatory approvals and broadened its distribution footprint in Asia and the US.

Genmin Limited has increased insider loans by A$0.5 million, reinforcing funding for its flagship Baniaka iron ore project in Gabon as it targets production in late 2026.

Chimeric Therapeutics reported a reduced net loss of $10.43 million for FY2025, driven by cost efficiencies and strategic project reprioritisation, while making significant clinical progress in its CAR T-cell and NK cell therapy programs.